Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
tiger====
That would be hard to do with 113 million in the bank.
not without another RS / IMO
HTBX will hit $50 per share, and nobody is going to stop that from happening.
Para
Been buying all morning. I got quite a bit at the low of today.
Good move, anything under $7 is a steal, will probably close above $7 today.
Yes! I added a quite a bit this week.
Good prices for taking a position.
Why is it whenever there is good news out the price of the stock goes down? Just venting.
NEWS -- Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results
Buy the dips folks it's a $50 stock.
im holding till at least $35.00
Me too! The obvious; buy low, sell high applies. There is every indication though that this stock should continue to only go up and up.
its a fricken miracle, im in the green
Sorry folks wrong board.
Looks like Rhinoceros Investments is following GMEV as well, posted this today:
$GMEV traded 20 million first few minutes. Stock up 17%. going to be making an impact in the vertical farming market. Going to be introducing game changing technology, #ERoots to the indoor #farming market.
Rhinoceros Investments:
A private company dedicated to the financial success and well-being of investors in public companies. We promote companies, ideas, and conservation.
@investrhino is their twitter feed
HTBX going to $50 per share, you can take that to the bank
Does any one know why htbx can't be bought on margin?
Yes a strong foundation has been put in by HTBX
This really is slow-turning but I think there's a tremendously solid foundation here. You can always build something really big when you have a great foundation.
Looks like HTBX is now officially on the path to $50 per share with the news release that they are commencing production of ZVX-60:
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.
EVERYONE SHOULD BE BUYING THIS STOCK BIG TIME IT IS JUST OVER A DOLLAR PRE REVERSE SPLIT OF 1 FOR 7
DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.
The Heat's presentation will be webcast live at 11:30 a.m. EST on Thursday, January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors - News/Events" tab on the Heat Biologics website at www.heatbio.com.
need the robin hood traders to go nuts
It seems like the timing is perfect to easily get to $50
Excellent, looking forward to the conference. HTBX is a $50 stock, killer T-cells are the number one fighting machines in the body.
NEWS -- Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021
DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.
The Heat's presentation will be webcast live at 11:30 a.m. EST on Thursday, January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors - News/Events" tab on the Heat Biologics website at http://www.heatbio.com.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/624982/Heat-Biologics-CEO-to-Participate-in-a-Fireside-Chat-at-the-B-Riley-Securities-Oncology-Investor-Conference-on-Jan-21-2021
Para====
With the news rel today you could be right======
NEWS -- Heat Biologics Commences Manufacturing Process for ZVX-60
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.
Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials. As previously announced, recent data generated with our collaborators at the University of Miami Miller School of Medicine confirmed ZVX-60 expression of gp96, OX40L and the COVID-19 Spike protein. We believe ZVX-60 holds promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, and look forward to working with Waisman to manufacture ZVX-60 for our first-in-human clinical trial."
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
For more information, please visit: http://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as ZVX-60 holding promise to enhance protection as a stand-alone vaccine or in combination with other vaccine approachesand the gp96 platform activating immune responses against cancer or pathogenic antigens. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of ZVX-60 to enhance protection as a stand-alone vaccine or in combination with other vaccine approaches, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
Note: View source version on accesswire.com to see the Company Balance Sheets:
https://www.accesswire.com/624776/Heat-Biologics-Commences-Manufacturing-Process-for-ZVX-60
It sure feels like they are doing a lot of things to get ready for something big to happen. The question is how long is it going to take. I'm long and know the only thing I can do is wait. GLTA!
"It is an honor to serve as Chief Financial Officer of Heat Biologics at this exciting stage in the Company's development. We are well positioned, both operationally and financially, to execute on a number of key milestones in 2021 that we believe will drive significant value for shareholders."
$50 here we come.
This guy who was just promoted to CFO wants to see HTBX at $50 per share. You can take that to the $50 bank.
NEWS -- Heat Biologics Promotes William L. Ostrander to Chief Financial Officer
DURHAM, NC / ACCESSWIRE / January 11, 2021 /Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021. Mr. Ostrander has over two decades of experience in financial management at public and private companies and previously served as the Company's Vice President of Finance since joining in September 2019.
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "The Board and I have enthusiastically promoted Mr. Ostrander to the role of Chief Financial Officer to reflect the tremendous work that Bill has done to navigate our finances and carefully manage our expenses. Bill's work has helped bring us to a stronger financial position than at any point in the Company's history-with over $117 million in cash and short-term investments at the end of the third quarter of 2020."
Bill Ostrander, further noted, "It is an honor to serve as Chief Financial Officer of Heat Biologics at this exciting stage in the Company's development. We are well positioned, both operationally and financially, to execute on a number of key milestones in 2021 that we believe will drive significant value for shareholders."
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
For more information, please visit: http://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding being well positioned, both operationally and financially, to execute on a number of key milestones in 2021 that will drive significant value for shareholders. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of execute on a number of key milestones, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
SOURCE: Heat Biologics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/623735/Heat-Biologics-Promotes-William-L-Ostrander-to-Chief-Financial-Officer
Now that is ridiculous and funny
Thanks, HTBX is a $50 stock, over 100 million in the bank , 22 million shares outstanding, the holy grail of immunotherapy
PR this morning:
Item 1.01. Entry into a Material Definitive Agreement
License Agreement Amendments
On December 31, 2020, Zolovax, Inc. (“Zolovax”), a wholly-owned subsidiary of Heat Biologics, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (“UM”) for the license and development of a portfolio of patents leveraging its UMIP-510 platform to target the COVID-19 virus and other infectious diseases. The License Agreement grants Zolovax exclusive, worldwide rights to research, develop, make, use or sell Licensed Products (as defined in the License Agreement) based upon patent-related rights. The term of the license is the later of the length of the last to expire patent or fifteen (15) years from the date of the first sale of a Licensed Product unless terminated earlier. As consideration for the rights granted in the License Agreement, Zolovax paid an upfront fee of $2,500, is obligated to pay certain annual payments and to pay royalties equal to a percentage (in the low-to-mid single digits) of net sales of Licensed Products. These royalty rates are subject to reduction if additional license rights from third parties are required to commercialize the Licensed Products. In the event of a sublicense to a third party, Zolovax is obligated to pay royalties to UM equal to a percentage of sublicense income. The License Agreement provides for diligence milestones that include Investigational New Drug (“IND”) submission to the Food and Drug Administration (“FDA”) or European Medicines Agency (“EMA”) within twenty four months of the effective date of the License Agreement, dosing first patient in a Phase 1 clinical trial within nine months of approval of an IND, and making commercially reasonable efforts towards obtaining regulatory marketing approval for a Licensed Product form either the FDA or EMA. The License Agreement also provides for commercial milestone payments of up to an aggregate of $7,750,000 upon the achievement of $10,00,000, $100,000,000 and $500,000,000 of cumulative net sales of License Products. The License Agreement provides that Zolovax may terminate the License Agreement upon ninety days’ notice to UM, UM has the right to terminate the License Agreement if Zolovax has engaged in certain bankruptcy events and each party has the right to terminate the License Agreement if the other party commits a material breach of the terms of the License Agreement, and such breach remains uncured for thirty days.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective January 4, 2021, William Ostrander, was promoted to Chief Financial Officer. Mr. Ostrander, age 53 joined the Company in September 2019 as the Company’s Vice President of Finance and Secretary in September 2019. Mr. Ostrander has over 22 years of experience in financial management at public and private companies. From November 2014 until joining the Company, Mr. Ostrander served as Executive Director of Finance at Liquidia Technologies, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint Inc., a private information products company that was acquired by LexisNexis. He also served as Senior Manager, Finance and held other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Mr. Ostrander holds a B.S. in Finance from Central Michigan University.
In connection with Mr. Ostrander’s new role as the Company’s Chief Financial Officer, effective January 4, 2021, the Company entered into an amendment (the “Ostrander Amendment”) to the Offer Letter, dated September 23, 2019, as amended on January 1, 2020. Pursuant to the Ostrander Amendment, Mr. Ostrander’s base salary has been increased to $275,000 (the “Base Salary”) and his bonus target has been increased to 30% of his Base Salary. In addition to a cash bonus equal to his target bonus paid at year end, on January 4, 2021, based upon the recommendations and guidance of the independent third party compensation consultant retained by the Compensation Committee, Mr. Ostrander was awarded a ten-year option to purchase 51,487 share of common stock ( the closing price of the Company’s common stock on the Nasdaq Capital Market on the date of the grant), at an exercise price of $5.67, of which one third vests immediately, one third vests on the one year anniversary of the date of grant and one third vests on the two year anniversary of the date of grant.
On January 4, 2021, we entered into a new employment agreement with Jeffrey Wolf (the “Wolf Agreement”) to continue to serve as our Chief Executive Office and President, which agreement replaces the employment agreement that we had entered into with Mr. Wolf on December 18, 2009, as amended on November 22, 2011, and further amended on each of January 20, 2014, January 11, 2016, January 1, 2017 and January 2, 2020.Purusnat to the terms of the Wolf Agreement, Mr. Wolf will receive an annual base salary of $540,000 per year. He also may receive, at the sole discretion of the board, an additional cash performance-based bonuses equal to up to 50% of his then outstanding base salary at the end of each year and a discretionary equity award, with the actual amount of his bonus to be increased in the sole discretion of the Board of Directors. In addition, he is to receive (i) an incentive cash bonus in an amount equal to 2% of the Transaction Consideration (as defined in the agreement) paid in connection with the consummation of a Change in Control (as defined in the agreement), provided that such Change in Control results in the stockholders of the Company receiving (or being entitled to receive, whether upon the consummation of the Change in Control or at a future date) transaction consideration worth at least 125% of the average closing trading price of the Company’s common stock during the 20 trading-day period immediately preceding the consummation of the Change in Control and (ii) an equity bonus in the form of additional stock options or restricted stock units or shares of restricted stock equal to 2% of the total fully-diluted equity of the Company if the market capitalization of the Company is equal to or exceeds a valuation of $500 million or more for fifteen (15) business days or longer. In addition, subject to certain condition, Mr. Wolf may also be entitled to receive equity in newly formed subsidiaries of the Company. If the Wolf Agreement is terminated for death or disability (as defined in the Wolf Agreement), he (or his estate in the event of death) will receive any unpaid base salary through the date of death or disability, any unpaid target bonus earned through date of termination and he shall be entitled to exercise any vested awards for the shorter of 24 months after termination and the remaining term of the award. If Mr. Wolf’s employment is terminated by us other than for Cause (as defined in the agreement) or by him for Good Reason (as defined in the Wolf Agreement), he will receive a payment of an amount equal to one (1) times his annual base salary plus his annual target bonus amount for the year of termination assuming payment in full of the annual target bonus, accelerated vesting of all unvested equity awards, extension of the time period in which to exercise awards equal to the lesser of 24 months after termination or the remaining term of the award and payment of COBRA premiums for the earlier or twelve months, the date he becomes eligible for other group benefits or his rights to COBRA expire. In addition, in the event the Company terminates Mr. Wolf’s employment upon or at any time in connection with a Change of Control Transaction (as defined in the Wolf Agreement), Mr. Wolf is entitled to a lump sum cash payment equal to 24 months of his current base pay, a cash payment equal to a pro-rated amount of his target annual target bonus for the year preceding termination, payment in full for COBRA for 12 months following termination and immediate vesting of the unvested portion of any outstanding equity awards and a period to exercise the awards equal to the lesser of 12 months after termination or the remaining term of the award. If within one year after the occurrence of a Change in Control, the Executive terminates his employment for Good Reason or the Company terminates his employment for any reason other than death, disability of cause Mr. Wolf is entitled to a lump sum cash payment equal to 24 months of his current base pay, a cash payment equal to his full target annual target bonus, payment in full for COBRA for 12 months following termination and immediate vesting of the unvested portion of any outstanding equity awards and a period to exercise the awards equal to the lesser of 24 months after termination or the remaining term of the award. Under the Wolf Agreement, Mr. Wolf has also agreed to non-competition provisions.
In addition to a cash bonus paid at year end, on January 4, 2021, based upon the recommendations and guidance of the independent third party compensation consultant retained by the Compensation Committee, Mr. Wolf was awarded a ten year option to purchase 147,980 shares of common stock, at an exercise price of $5.67 (the closing price of the Company’s common stock on the Nasdaq Capital Market on the date of the grant) all of which vests on the two year anniversary of the date of grant and 228,100 shares of restricted stock, of which half vests immediately and the remaining half vests on the one year anniversary of the date of grant.
On January 4, 2021, based upon the recommendations and guidance of the independent third party compensation consultant retained by the Compensation Committee, the Board also awarded the following equity compensation to the non-executive members of the Board and its Committees: John K.A. Prendergast, Ph.D., the lead independent director, was awarded 138,272 shares of restricted common stock (including a one-time equity refresher of 105,820 shares of restricted common stock); John Monahan, Ph.D., was awarded an option to purchase 65,217 shares of common stock (including a one-time equity refresher of an option to purchase 45,766 shares of common stock), and Edward B. Smith, III was awarded an option to purchase 65,217 shares of common stock (including a one-time equity refresher of an option to purchase 45,766 shares of common stock). Each option is exercisable for a period of ten years from the date of grant, vests immediately and has an exercise price of $5.67 per share (the closing price of the Company’s common stock on the Nasdaq Capital Market on the date of the grant). The annual cash compensation for directors for 2021 is to remain the same as it was for the prior year as disclosed in the Company’s 2020 proxy statement other than the annual cash retainer that was increased by $5,000 per non-executive director year to $40,000 per non-executive director per year.
On December 31, 2020, the Company entered into a Separation Agreement with Jeff T. Hutchins, Ph.D., the Company’s former Chief Scientific and Operating Officer (the “Hutchins Separation Agreement”) which provides for a payment to Dr. Hutchins of $110,000. The separation agreement contains non-disparagement obligations, non-solicitation and a standard release of claims on the part of Dr. Hutchins.
The foregoing summaries of each of the License Agreement, the Ostrander Amendment, the Wolf Agreement, the form of Restricted Stock Agreement and the Hutchins Separation Agreement, does not purport to be complete and each is qualified in its entirety by reference to the License Agreement, the Ostrander Amendment, the Wolf Agreement and the Hutchins Separation Agreement, a copy of each of which is filed as Exhibit 10.1, 10.2, 10.3, 10.4 and 10.5 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K.
Exhibit
Number
Exhibit Description
10.1+
Exclusive License Agreement between the University of Miami and Zolovax, Inc. dated as of December 31, 2020.
10.2
Amendment to Offer Letter between Heat Biologics, Inc. and William Ostrander, dated as of January 4, 2021.
10.3
Employment Agreement between Heat Biologics, Inc. and Jeffrey Wolf, dated as of January 4, 2021.
10.4
Form of Restricted Stock Agreement
10.5
Separation Agreement dated December 31, 2020 between Heat Biologics, Inc. And Jeff Hutchins.
+ Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to confidential treatment.
It seems this stock is not going anywhere until the clinical trials are complete and there is positive news. Hoping for the best. Good luck to all!
Is gone.
Up it goes.
Most talked about stock in January- be ready.
bige
Sorry to hear about your wife.
Agreed Paraceratherium! My wife of 13 years just died from cancer two weeks ago. Immunotherapy and fighting with T cells I believe 100% is the way to go in the future. I wish it could have helped my wife as well as thousands and thousands of other people in the future. God's speed to HTBX.
warren buffet said " stock market is a vessel to transfer wealth from the inpatient
to the patient". or something like that LOL
Folks, the consolidation of 1 for 7 with $113 million in the bank was done to get the stock over $5 per share so that institutional investors could jump on board to help push this stock to $50 per share.
Immunotherapy is the future for medicine, and using killer T-cells to fight disease/infection is the ultimate cellular fighting machine.
Keep buying till this stock is $50.
DIS
I am sure they will be but I hope at higher price.
there will be MANY MORE “buying opportunities” in the next few months
cmeny
Over 100 million in the bank=====
How much cash does HTBX have on hand? Didnt they raise a bunch of money?
I think our patience is about to pay off big time.= JMO
I have heavily invested in this company for over two years now. Definitely a test of patience!
hope your right but this cycle seems just like the one 2 years or so ago
Yes is a big time joke like about 15.00 to 20.00 dollars joke
Followers
|
155
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6042
|
Created
|
01/26/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |